Electronic Supplementary Material (ESI) for RSC Medicinal Chemistry. This journal is © The Royal Society of Chemistry 2021

1

Content

1	Cł	nemistry – Experimental Procedures and Data	2
1.	1	General Procedures	2
1.2	2	Synthesis of Itaconate building blocks	4
1.3	3	Synthesis of Itaconate-linked ET-CORMs (ItaCORMs)	6
1.4	4	In situ quantification of CO-release	16
1.	5	NMR-Spectra	21
1.0	6	Crystal data and structure refinement	31
2	Bi	ology – Experimental Procedures	. 33
2.	1	Animals	33
2.2	2	Isolation of primary dendritic cells	33
2.3	3	Viability	33
2.4	4	Western blot	34
2.	5	Analyses of cytokines	34
3	Bi	ology - Results	. 34
3.	1	Determination of cell viability	34
3.2	2	ELISA	35
4	Re	eferences	. 36

1 Chemistry – Experimental Procedures and Data

1.1 General Procedures

Inert gas

Unless otherwise stated, all reactions were run under an inert atmosphere using *Schlenk* technique and argon 4.6 of the company *Linde* (99.996%, <1 ppm H₂O, <1 ppm O₂). Before being used glassware was evacuated, heated out with a heat gun and then flushed with argon three times.

Solvents and reagents

Unless otherwise stated all chemicals and solvents were purchased from commercial suppliers (*Acros, Alfa-Aesar, Carbolution, Merck, Rockwood-Lithium, Sigma-Aldrich, TCI* and *VWR*) and were used without further purification. Di*iso*propylamine, hexamethyldisalazane and 2-cyclohexenone were distilled and stored under argon atmosphere. The concentration of *n*-butyllithium was determined by titration.¹ Non-absolute solvents were distilled before use. Absolute THF and toluene were obtained by distillation under argon atmosphere over sodium with benzophenone used as indicator. CH₂Cl₂ was dried over CaCl₂ and distilled on the day of use. Other solvents were used without further purification unless otherwise noted.

Removal of solvents

Solvents were removed under reduced pressure using a rotary evaporator of the company *Büchi* and a membrane pump. The temperature of the water bath was set to 40 °C. Residual solvents were then removed under oil pump vacuum.

Nuclear magnetic resonance

NMR spectra (¹H and ¹³C) were recorded on the devices Avance II 300 (¹H NMR: 300 MHz, ¹³C NMR: 75 MHz), Avance 400 (¹H NMR: 400 MHz, ¹³C NMR: 100 MHz), Avance III 499 (¹H NMR: 500 MHz) and Avance AVIII-HD 500 (¹H NMR: 500 MHz, ¹³C NMR: 125 MHz) of the company *Bruker*. Proton as well as carbon chemical shifts δ are reported in ppm (parts per million) relative to tetramethylsilane. All spectra were measured at room temperature. The multiplicity of signals is described with "s" for singlet, "d" for doublet, "t" for triplet as well as "m" for multiplet and "br" for broad signal. Coupling constants are given in Hertz. The assignment of signals was done using suitable 2D-NMR spectra (COSY, HMQC/HSQC, HMBC, NOESY).

Thin layer chromatography (TLC)

Thin layer chromatography was performed using aluminium sheets coated with silica gel 60 F_{254} from the company *Merck*. The spots were visualised with UV-light (254 nm) and basic KMnO₄ solution or ninhydrin solution as staining agents. The eluent mixtures are given in volume fractions for each experiment.

Flash column chromatography

Silica gel 60 (0.035 - 0.07 mm, 60 Å) from the company *Acros* was used as stationary phase for the column chromatography. The silica gel was prepared using the suitable eluent mixture and then compressed using pressure. The eluent mixtures are given in volume fractions for each experiment.

Fourier-Transform-Infrared spectroscopy (FT-IR)

FT-IR spectra were recorded at room temperature on a SpectrumTwo spectrometer from *Perkin-Elmer* with ATR technique. The measured bands are reported in cm⁻¹ using the following abbreviations: "w" for weak, "m" for medium, "s" for strong and "vs" for very strong signals.

Gas chromatography with mass spectrometric detector (GC-MS)

The GC-MS spectra were measured on an *Agilent Hewlett Packard* 6890 Series Plus instrument with injector and auto sampler with a HP5973 Series mass selective detector. H₂ was used as carrier gas. A capillary column *Macherey-Nagel* Optima 1 MS (30 mm x 0.25 mm, Ø) was used. Measurements were performed using the temperature programme (50-300MS): 50 °C (2 min), heating rate: 25 °C/min, 300 °C (5 min), 320 °C (5 min).

High resolution Electron-Spray-Ionization mass-spectrometry

HR-ESI-MS spectra were measured on a THERMO Scientific LTQ Orbitrap XL-FTMS Analyser of the company *Thermo Fischer*. Ionization was achieved via electrospray method applying a spray voltage of 3.4 kV. The capillary and tube lens voltage was set to 3.0 V.

Melting point

The uncorrected melting points of solids were measured using a B-545 system of the company *Büchi* with a heating rate of 1 °C/min.

1.2 Synthesis of Itaconate building blocks

1.2.1 Synthesis of diethyl itaconate (DEI, 13)



A solution of 4-ethyl itaconate (**12a**) (5.00 g, 31.6 mmol, 1.00 eq.) in CH_2CI_2 (160 mL) was cooled to 0 °C. DIC (6.85 mL, 44.3 mmol, 1.4 eq.), DMAP (1.2 mg, 9.48 mmol, 0.3 eq.) and EtOH (9.23 mL, 158 mmol, 5.00 eq.) were added subsequently. The resulting reaction mixture was stirred at 0 °C for 10 min and then warmed up to room temperature and stirred for 4.5 h. The reaction mixture was filtered over *Celite* with CH_2CI_2 and concentrated under reduced pressure. The crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 5:1) and the desired product was obtained in a yield of 4.86 g (26.1 mmol, 83%) in form of a colourless oil.

0

M (C ₉ H ₁₄ O)	186.21 g/mol.	$9 \xrightarrow{0} 0 \xrightarrow{4} 1 \xrightarrow{3} 1 \xrightarrow{6} 7$
Yield	4.86 g (26.1 mmol, 83%).	Ö II 5
R _f	0.67 (SiO ₂ , Cyhex/EtOAc; 3:1).	
¹ H NMR	(300 MHz, CDCl ₃): δ [ppm] = 6.32 (s, 1H, H-5 (q, <i>J</i> = 7.1 Hz, 2H, H-6), 4.16 (q, <i>J</i> = 7.1, 2H 2H, C-3), 1.30/1.26 (2 x t, <i>J</i> = 7.1 Hz, 6H, H-7	5a), 5.69 (s, 1H, H-5b), 4.22 I, H-8), 3.33 (d, <i>J</i> = 1.1 Hz, 7, H-9).
¹³ C NMR	(75 MHz, CDCl ₃): δ [ppm] = 170.8 (C-4), 166 (C-5), 61.1 (C-6), 61.0 (C-8), 37.9 (C-3), 2 x	.3 (C-1), 134.3 (C-2), 128.2 14.3 (C-7, C-9).
FT-IR	(ATR): $\tilde{\nu}$ [cm ⁻¹] = 2983 (w), 2940 (w), 2908 (w) (vs), 1640 (m), 1478 (w), 1468 (w), 1447 (w) (m), 1335 (m), 1316 (m), 1300 (m), 1255 (m) (w), 1030 (s), 947 (m), 887 (w), 861 (m), 818 (w), 648 (w), 629 (w), 573 (w), 557 (w), 515 (w)	w), 2876 (w), 1737 (s), 1716), 1420 (w), 1393 (w), 1369), 1189 (s), 1144 (vs), 1096 8 (m), 786 (w), 762 (w), 741 (w), 432 (w).

The spectroscopic data are in accordance with the literature.²

1.2.2 Synthesis of 1-Ethyl itaconate (1-El, 11a)



According to a modified procedure by *K. Achiwa*,³ diethyl itaconate (**DEI**, **13**) (800 mg, 4.30 mmol, 1.00 eq.) was dissolved in formic acid (8 mL) and mixed with MeSO₃H (418 μ L, 6.44 mmol, 1.50 eq.). The reaction mixture was heated to 110 °C and stirred for 45 min. After being cooled to room temperature over 1.5 h, the reaction mixture was poured into ice water and extracted with CH₂Cl₂ (4 x 20 mL). The combined organic layers were dried over MgSO₄ and the solvent was removed *in vacuo*.

The crude product was purified by *Kugelrohr* distillation and the desired product **11a** was obtained in a yield of 296 mg (1.87 mmol, 44%) in form of a clear colourless oil.

M (C7H10O4)	158.15 g/mol.	$HO_{4}^{3} \xrightarrow{0}_{1}^{6} \xrightarrow{6}_{7}$
Yield	296 mg (1.87 mmol, 44%).	
¹ H NMR	(300 MHz, CDCl ₃): δ [ppm] = 6.36 (d, <i>J</i> = 1.0 Hz, 1.2 Hz, 1H, H-5b), 4.24 (q, <i>J</i> = 7.1 Hz, 2H, H-6), 3 H-3), 1.30 (t, <i>J</i> = 7.1 Hz, 3H, H-7).	1H, H-5a), 5.73 (q, <i>J</i> = 3.39 (d, <i>J</i> = 1.1 Hz, 2H,
¹³ C NMR	(75 MHz, CDCl ₃): δ [ppm] = 176.9 (C-4), 166.3 (C (C-5), 61.4 (C-6), 37.7 (C-3), 14.2 (C-7).	C-1), 133.6 (C-2), 128.9
FT-IR	(ATR): $\tilde{\nu}$ [cm ⁻¹] = 3494 (br), 3108 (br), 2985 (w 2874 (w), 2646 (w), 1707 (vs), 1637 (m), 1468 (w 1397 (m), 1372 (m), 1335 (m), 1316 (m), 1300 (1150 (s), 1095 (w), 1024 (m), 957 (m), 946 (m), (w), 817 (m), 786 (w), 728 (m), 623 (w), 573 (w),), 2938 (w), 2908 (w), v), 1446 (w), 1420 (m), m), 1203 (s), 1175 (s), 909 (w), 885 (w), 861 533 (w), 448 (w).

The spectroscopic data are in accordance with the literature.²

1.3 Synthesis of Itaconate-linked ET-CORMs (ItaCORMs)

1.3.1 Synthesis of ItaCORM 1a



In a *Schlenk* tube, 1-ethyl itaconate (**11a**) (28.2 mg, 178 μ mol, 1.40 eq.) was dissolved in CH₂Cl₂ (0.6 mL) and cooled to 0 °C. *Ghosez*'s reagent (26.3 μ L, 191 μ mol, 1.50 eq.) was added and the reaction mixture was stirred for 1.5 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9a** (50 mg, 127 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (0.6 mL), cooled to 0 °C and TBAF (1 M in THF, 127 μ L, 127 μ mol, 1.00 eq.) was added dropwise (M2). Upon stirring the mixture for 15 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 1 h and then stirred at room temperature for 16 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 20:1 to 5:1). The desired product **ItaCORM 1a** was obtained in form of a clear yellow oil in a yield of 36 mg (95.7 μ mol, 75%).

 M ($C_{16}H_{16}FeO_7$)
 376.14 g/mol.

 Yield
 36 mg (95.7 μ mol, 75%)

 R_f
 0.79 (SiO₂, Cyhex/EtOAc; 5:1).

 ¹H NMR
 (500 MHz, CDCl₃): δ [ppm] = 6.38 (d, J = 0.8 Hz, 1H, H-5a), 5.77 (d, J = 1.1 Hz, 1H, H-5b), 5.52 (ddd, J = 6.7, 2.1, 0.8 Hz, 1H, H-9), 4.24 (q, J = 7.1 Hz, 2H, H-6), 3.45 (dd, J = 3.7, 1.1 Hz, 2H, H-3), 3.38 (dt, J = 3.8, 2.3 Hz, 1H, H-13), 2.85 (ddd, J = 6.3, 3.5, 2.4 Hz, 1H, H-10), 1.87 – 1.78 (m, 1H, H-12a), 1.79 – 1.70 (m, 1H, H-12b), 1.60 – 1.51 (m, 2H, H-11), 1.31 (t, J = 7.1 Hz, 3H, H-7).

¹³**C NMR** (125 MHz, CDCl₃): δ [ppm] = 210.8 (C-14), 170.2 (C-4), 166.0 (C-1), 133.3 (C-2), 129.1 (C-5), 128.5 (C-8), 79.8 (C-9), 61.4 (C-6), 59.1 (C-13), 52.2 (C-10), 37.9 (C-3), 24.7 (C-12), 23.6 (C-11), 14.3 (C-7).

HR-MS (ESI) calc.: [M+Na]⁺ = 399.01377 amu found: 399.01380 amu.

FT-IR (ATR): $\tilde{v} [cm^{-1}] = 3007 (w)$, 2986 (w), 2935 (w), 2903 (w), 2887 (w), 2858 (w), 2045 (vs), 1958 (vs), 1763 (m), 1714 (m), 1639 (w), 1468 (w), 1458 (m), 1430 (w), 1420 (w), 1394 (w), 1372 (w), 1336 (m), 1316 (m), 1255 (w), 1236 (w), 1207 (m), 1169 (s), 1120 (s), 1076 (w), 1025 (m), 996 (w), 958 (w), 925 (w), 900 (w), 882 (w), 861 (w), 839 (w), 818 (w), 791 (w), 757 (w), 725 (w), 678 (w), 618 (m), 608 (s), 571 (s), 507 (m), 460 (w), 416 (w).

1.3.2 Synthesis of ItaCORM 1b



In a *Schlenk* tube, 1-ethyl itaconate (**11a**) (84.7 mg, 535 μ mol, 1.40 eq.) was dissolved in CH₂Cl₂ (1.3 mL) and cooled to 0 °C. *Ghosez*'s reagent (79.0 μ L, 573 μ mol, 1.50 eq.) was added and the reaction mixture was stirred for 1.5 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9b** (150 mg, 382 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.3 mL), cooled to 0 °C and TBAF (1 M in THF, 382 μ L, 382 μ mol, 1.00 eq.) was added dropwise (M2). Upon stirring the mixture for 15 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 5 min and then stirred at room temperature for 20 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 20:1 to 5:1). The desired product **ItaCORM 1b** was obtained in form of a clear yellow oil in a yield of 131 mg (348 μ mol, 91%).

M (C ₁₆ H ₁₆ FeO ₇)	376.14 g/mol.	0
Yield	131 mg (348 <i>µ</i> mol, 91%)	
R _f	0.65 (SiO ₂ , Cyhex/EtOAc; 5:1).	12 - 10 - 14 - 11 - 11 - 14
¹ H NMR	(600 MHz, CDCl ₃): δ [ppm] = 6.34 (d, J = 1.0 J = 1.1 Hz, 1H, H-5b), 5.39 (dd, J = 4.5, 1.3 J = 5.7, 4.5, 1.0 Hz, 1H, H-10), 4.21 (q, J = 7.1	Hz, 1H, H-5a), 5.71 (d, Hz, 1H, H-9), 5.10 (ddd, Hz, 2H, H-6), 3.37 – 3.29

(m, 2H, H-3), 3.11 – 3.07 (m, 1H, H-11), 2.18 – 2.11 (m, 1H, H-13a), 1.91 – 1.77 (m, 2H, H-12a, H-13b), 1.70 – 1.63 (m, 1H, H-12b), 1.29 (t, *J* = 7.1 Hz, 3H, H-7).

¹³**C NMR** (150 MHz, CDCl₃): δ [ppm] = 211.3 (C-14), 210.7 (C-14), 169.1 (C-4), 166.1 (C-1), 133.7 (C-2), 128.8 (C-5), 103.6 (C-8), 80.7 (C-9 or C-10), 80.4 (C-9 or C-10), 61.2 (C-6), 60.5 (C-11), 38.1 (C-3), 26.8 (C-13), 24.2 (C-12), 14.3 (C-7).

HR-MS (ESI) calc.: [M+Na]⁺ = 399.01377 amu found: 399.01365 amu.

FT-IR (ATR): $\tilde{v} [cm^{-1}] = 2986$ (w), 2938 (w), 2914 (w), 2896 (w), 2859 (w), 2047 (vs), 1966 (vs), 1752 (m), 1718 (m), 1640 (w), 1473 (w), 1457 (w), 1443 (w), 1427 (w), 1380 (w), 1371 (w), 1330 (w), 1317 (m), 1242 (w), 1182 (m), 1165 (m), 1133 (m), 1111 (m), 1068 (w), 1029 (w), 1007 (w), 956 (w), 897 (w), 861 (w), 818 (w), 788 (w), 769 (w), 748 (w), 639 (w), 611 (m), 562 (m), 517 (w), 490 (w), 457 (w), 411 (w).

1.3.3 Synthesis of ItaCORM 2a



In a *Schlenk* tube, 4-ethyl itaconate (**12a**) (84.7 mg, 535 μ mol, 1.40 eq.) was dissolved in CH₂Cl₂ (1.5 mL) and cooled to 0 °C. *Ghosez*'s reagent (79.0 μ L, 573 μ mol, 1.50 eq.) was added and the reaction mixture was stirred for 2.0 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9a** (150 mg, 382 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.5 mL), cooled to 0 °C and TBAF (1 M in THF, 382 μ L, 382 μ mol, 1.00 eq.) was added dropwise (M2). Upon stirring the mixture for 15 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 15 min and then stirred at room temperature for 20 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 6:1). The desired product **ItaCORM 2a** was obtained in form of a clear yellow oil in a yield of 140 mg (372 μ mol, 97%).

M ((C16H16FeO7) 376.14 g/mol.
------------	-------------	-----------------

Yield 140 mg (372 µmol, 97%)

R_f 0.73 (SiO₂, Cyhex/EtOAc; 5:1).

¹**H NMR** (500 MHz, CDCl₃): δ [ppm] = 6.42 (s, 1H, H-5a), 5.84 (s, 1H, H-5b), 5.55 (dd, *J* = 6.7, 2.0 Hz, 1H, H-9), 4.17 (qd, *J* = 7.2, 2.0 Hz, 2H, H-6), 3.44 – 3.32 (m, 3H, H-3, H-13), 2.87 (dt, *J* = 6.3, 2.9 Hz, 1H, H-10), 1.89 – 1.81 (m, 1H, H-12a), 1.81 – 1.72 (m, 1H, H-12b), 1.62 – 1.53 (m, 2H, H-11), 1.27 (t, *J* = 7.1 Hz, 3H, H-7).

¹³**C NMR** (125 MHz, CDCl₃): δ [ppm] = 210.8 (C-14), 170.5 (C-4), 165.8 (C-1), 133.1 (C-2), 130.6 (C-5), 128.7 (C-8), 80.0 (C-9), 61.3 (C-6), 59.3 (C-13), 52.2 (C-10), 37.7 (C-3), 24.7 (C-12), 23.6 (C-11), 14.3 (C-7).

HR-MS (ESI) calc.: $[M+Na]^{+} = 399.01377$ amu found: 399.01350 amu.

FT-IR $(ATR): \tilde{v} [cm^{-1}] = 2983 (w), 2935 (w), 2900 (w), 2855 (w), 2047 (vs), 1967
(vs), 1737 (m), 1641 (w), 1470 (w), 1459 (m), 1428 (w), 1393 (w), 1367
(w), 1337 (m), 1315 (m), 1255 (w), 1172 (m), 1124 (m), 1076 (w), 1032
(w), 961 (w), 949 (w), 930 (w), 879 (w), 855 (w), 807 (w), 775 (w), 736
(w), 685 (w), 620 (m), 572 (m), 515 (w), 504 (w), 461 (w).$

1.3.4 Synthesis of ItaCORM 2b



In a *Schlenk* tube, 4-ethyl itaconate (**12a**) (84.7 mg, 535 μ mol, 1.40 eq.) was dissolved in CH₂Cl₂ (1.3 mL) and cooled to 0 °C. *Ghosez*'s reagent (79.0 μ L, 573 μ mol, 1.50 eq.) was added and the reaction mixture was stirred for 1.5 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9b** (150 mg, 382 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.3 mL), cooled to 0 °C and TBAF (1 M in THF, 382 μ L, 382 μ mol, 1.00 eq.) was

e(CO)₃

added dropwise (M2). Upon stirring the mixture for 15 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 10 min and then stirred at room temperature for 20 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 6:1). The desired product **ItaCORM 2b** was obtained in form of a clear yellow oil in a yield of 134 mg (356 μ mol, 93%).

M (C₁₆H₁₆FeO₇) 376.14 g/mol.

 Yield
 134 mg (356 μmol, 93%)

R_f 0.65 (SiO₂, Cyhex/EtOAc; 5:1).

¹**H NMR** (500 MHz, CDCl₃): δ [ppm] = 6.34 (d, J = 0.8 Hz, 1H, H-5a), 5.72 (d, J = 1.1 Hz, 1H, H-5b), 5.43 (dd, J = 4.5, 1.2 Hz, 1H, H-9), 5.13 (ddd, J = 6.1, 4.7, 0.9 Hz, 1H, H-10), 4.15 (q, J = 7.1 Hz, 2H, H-6), 3.33 (s, 2H, H-3), 3.11 (dddd, J = 6.3, 3.8, 2.3, 1.5 Hz, 1H, H-11), 2.19 – 2.12 (m, 1H, H-13a), 1.93 – 1.83 (m, 2H, H-12a, H-13b), 1.72 – 1.60 (m, 1H, H-12b), 1.26 (t, J = 7.1 Hz, 3H, H-7).

 $e(CO)_3$

¹³**C NMR** (125 MHz, CDCl₃): δ [ppm] = 211.3 (C-14), 169.1 (C-4), 164.6 (C-1), 133.9 (C-2), 129.0 (C-5), 103.8 (C-8), 80.8 (C-9 or C-10), 80.5 (C-9 or C-10), 61.1 (C-6), 60.5 (C-11), 37.9 (C-3), 26.8 (C-13), 24.3 (C-12), 14.3 (C-7).

HR-MS (ESI) calc.: $[M+Na]^+ = 399.01377$ amu found: 399.01368 amu.

FT-IR (ATR): $\tilde{v} [cm^{-1}] = 3671 (w), 2986 (w), 2938 (w), 2909 (w), 2861 (w), 2048 (vs), 1969 (vs), 1734 (m), 1642 (w), 1473 (w), 1427 (w), 1385 (w), 1370 (w), 1329 (w), 1317 (w), 1256 (w), 1183 (m), 1137 (m), 1069 (w), 1033 (w), 1006 (w), 952 (w), 867 (w), 812 (w), 758 (w), 612 (m), 561 (m), 518 (w), 485 (w), 461 (w).$

1.3.5 Synthesis of ItaCORM 3a



In a *Schlenk* tube, 1-methyl itaconate (**11b**) (107 mg, 742 μ mol, 1.43 eq.) was dissolved in CH₂Cl₂ (1.0 mL) and cooled to 0 °C. *Ghosez*'s reagent (120 μ L, 906 μ mol, 1.74 eq.) was added and the reaction mixture was stirred for 1 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9a** (204 mg, 520 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.0 mL), cooled to 0 °C and TBAF (1 M in THF, 520 μ L, 520 μ mol, 1.0 eq.) was added dropwise (M2). Upon stirring the mixture for 10 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 10 min and then stirred at room temperature for 21 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 20:1 to 7:1). The desired product **ItaCORM 3a** was obtained in form of a clear yellow oil in a yield of 63 mg (170 μ mol, 33%).

M (C₁₅H₁₄FeOァ)	362.12 g/mol.	0 3 2 6
(J	$\begin{array}{c} \uparrow_4 \\ \downarrow \end{array}$
Yield	63 mg (170 <i>μ</i> mol, 33%)	
R _f	0.57 (SiO ₂ , Cyhex/EtOAc; 6:1).	11 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -
¹ H NMR	(500 MHz, CDCl ₃): δ [ppm] = 6.38 (s, 1	H, H-5a), 5.79 (s, 1H, H-5b), 5.52
	(dd, <i>J</i> = 6.6, 1.5 Hz, 1H, H-8), 3.78 (s, 5	3, H-6), 3.49 – 3.41 (m, 2H, H-3),
	3.38 (dt, J = 3.8, 2.3 Hz, 1H, H-12), 2.8	7 – 2.83 (m, 1H, H-9), 1.86 – 1.79
	(m, 1H, H-11a), 1.79 – 1.71 (m, 1H, H-	11b), 1.58 – 1.48 (m, 2H, H-10).
¹³ C NMR	(125 MHz, CDCl ₃): δ [ppm] = 210.8 (0	C-13), 170.2 (C-4), 166.5 (C-1),
	133.1 (C-2), 129.4 (C-5), 128.5 (C-7), 7	9.8 (C-8), 59.1 (C-12), 52.4 (C-9),
	52.2 (C-6), 37.9 (C-3), 24.7 (C-11), 23.	6 (C-10).
HR-MS (ESI)	calc.: [M+Na] ⁺ = 384.99812 amu	found: 384.99806 amu.
FT-IR	(ATR): ν̃ [cm ⁻¹] = 3010 (w), 2954 (w), 29	940 (w), 2902 (w), 2881 (w), 2857
	(w), 2046 (s), 1962 (vs), 1763 (w), 174	4 (m), 1726 (m), 1646 (w), 1474
	(w), 1458 (w), 1438 (w), 1395 (w), 135	56 (w), 1321 (w), 1263 (m), 1216

(w), 1164 (m), 1110 (m), 1076 (w), 1010 (w), 996 (w), 974 (w), 924 (w), 899 (w), 864 (w), 840 (w), 818 (w), 770 (w), 679 (w), 619 (m), 608 (m), 572 (m), 513 (w), 461 (w).

1.3.6 Synthesis of ItaCORM 3b



In a *Schlenk* tube, 1-methyl itaconate (**11b**) (56 mg, 389 μ mol, 1.47 eq.) was dissolved in CH₂Cl₂ (1.0 mL) and cooled to 0 °C. *Ghosez*'s reagent (51 μ L, 389 μ mol, 1.47 eq.) was added and the reaction mixture was stirred for 1 h (M1).

In separate *Schlenk* tube, complex *rac*-**9b** (104 mg, 265 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.3 mL), cooled to 0 °C and TBAF (1 M in THF, 280 μ L, 280 μ mol, 1.06 eq.) was added dropwise (M2). Upon stirring the mixture for 15 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 10 min and then stirred at room temperature for 22 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 6:1). The desired product **ItaCORM 3b** was obtained in form of a clear yellow oil in a yield of 76 mg (210 μ mol, 79%). The product crystallized upon storage.

M (C ₁₅ H ₁₄ FeO ₇)	362.12 g/mol.	0
Yield	76 mg (210 μmol, 79%)	12 7 8 5 5 6 6 6 6 12 12 8 12 12 12 12 12 12 12 12
R _f	0.42 (SiO ₂ , Cyhex/EtOAc; 5:1).	11 9 13 10 Fe(CO) ₃ 11 10
¹ H NMR	(600 MHz, CDCl₃): δ [ppm] = 6.35 (s, 1H H-5b), 5.39 (d, <i>J</i> = 4.4 Hz, 1H, H-8), 5.11 (s, 3H, H-6), 3.39 – 3.26 (m, 2H, H-3), 3.1 2.09 (m, 1H, H-12a), 1.92 – 1.75 (m, 2H, H	H, H-5a), 5.82 – 5.57 (m, 1H, I (t, <i>J</i> = 5.5 Hz, 1H, H-9), 3.75 I 2 – 3.06 (m, 1H, H-10), 2.19 – H-11a, H-12b), 1.71 – 1.62 (m,
		· /· (·

1H, H-11b).

¹³ C NMR	(150 MHz, CDCl ₃): δ [ppm] = 211.3 (C-13), 169.0 (C-4), 166.6 (C-1),
	133.4 (C-2), 129.2 (C-5), 103.6 (C-7), 80.8 (C-8 or C-9), 80.3 (C-8 or
	C-9), 60.5 (C-10), 52.3 (C-6), 38.1 (C-3), 26.8 (C-12), 24.2 (C-11).

HR-MS (ESI) calc.: $[M+Na]^+ = 384.99812$ amu found: 384.99793 amu.

FT-IR (ATR): $\tilde{\nu} [cm^{-1}] = 3008$ (w), 2953 (w), 2917 (w), 2894 (w), 2858 (w), 2044 (s), 1957 (s), 1749 (s), 1723 (s), 1640 (m), 1468 (m), 1455 (m), 1439 (m), 1384 (m), 1339 (m), 1318 (m), 1262 (m), 1244 (m), 1202 (m), 1170 (s), 1132 (s), 1109 (s), 1067 (m), 1030 (w), 1006 (m), 956 (m), 913 (w), 865 (m), 840 (m), 817 (m), 791 (w), 768 (w), 750 (w), 711 (w), 638 (m), 609 (s), 560 (s), 518 (m).

m.p. 33.1 – 35.4 °C.

1.3.7 Synthesis of ItaCORM 4a



In a *Schlenk* tube, 4-methyl itaconate (**12b**) (~90%, 64 mg, 400 μ mol, 1.52 eq.) was dissolved in CH₂Cl₂ (1.0 mL) and cooled to 0 °C. *Ghosez*'s reagent (51 μ L, 389 μ mol, 1.48 eq.) was added and the reaction mixture was stirred for 2.0 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9a** (103 mg, 263 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.0 mL), cooled to 0 °C and TBAF (1 M in THF, 0.29 mL, 0.29 mmol, 1.1 eq.) was added dropwise (M2). Upon stirring the mixture for 10 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 30 min and then stirred at room temperature for 16.5 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 6:1). The desired product **ItaCORM 4a** was obtained in form of a clear yellow oil in a yield of 77 mg (213 μ mol, 81%).

 M (C₁₅H₁₄FeO₇)
 362.12 g/mol.

 Yield
 77 mg (213 μmol, 81%)



R _f 0.41 (SiO ₂ , Cyhex/EtOAc; 5	5:1).
---	-------

- ¹**H NMR** (500 MHz, CDCl₃): δ [ppm] = 6.43 (s, 1H, H-5a), 5.85 (s, 1H, H-5b), 5.56 (dd, J = 6.6, 1.8 Hz, 1H, H-8), 3.71 (s, 3H, H-6), 3.57 3.26 (m, 3H, H-3, H-12), 2.88 (dt, J = 6.3, 3.0 Hz, 1H, H-9), 1.95 1.72 (m, 1H, H-12), 1.71 1.44 (m, 2H, H-11).
- ¹³**C NMR** (125 MHz, CDCl₃): δ [ppm] = 210.8 (C-13), 170.9 (C-4), 165.7 (C-1), 132.9 (C-2), 130.8 (C-5), 128.7 (C-7), 80.0 (C-8), 59.3 (C-12), 52.3 (C-9), 52.3 (C-6), 37.4 (C-3), 24.7 (C-11), 23.6 (C-10).

HR-MS (ESI) calc.: [M+Na]⁺ = 384.99812 amu found: 384.99808 amu.

FT-IR (ATR): $\tilde{v} [cm^{-1}] = 3007$ (w), 2954 (w), 2933 (w), 2906 (w), 2856 (w), 2047 (s), 1966 (vs), 1741 (m), 1641 (w), 1459 (w), 1437 (w), 1401 (w), 1343 (w), 1317 (w), 1256 (w), 1171 (m), 1124 (m), 1074 (w), 1017 (w), 997 (w), 958 (w), 945 (w), 928 (w), 896 (w), 872 (w), 843 (w), 808 (w), 777 (w), 745 (w), 686 (w), 619 (m), 610 (m), 572 (m), 515 (w), 461 (w).

1.3.8 Synthesis of ItaCORM 4b



In a *Schlenk* tube, 1-methyl itaconate (**12b**) (~90%, 62 mg, 387 μ mol, 1.51 eq.) was dissolved in CH₂Cl₂ (1.0 mL) and cooled to 0 °C. *Ghosez*'s reagent (51 μ L, 389 μ mol, 1.51 eq.) was added and the reaction mixture was stirred for 1 h (M1).

In a separate *Schlenk* tube, complex *rac*-**9b** (101 mg, 257 μ mol, 1.00 eq.) was dissolved in CH₂Cl₂ (1.0 mL), cooled to 0 °C and TBAF (1 M in THF, 0.28 mL, 280 μ mol, 1.09 eq.) was added dropwise (M2). Upon stirring the mixture for 10 min it was transferred dropwise into M1 at 0 °C. The resulting reaction mixture was stirred at 0 °C for 1 h and then stirred at room temperature for 23 h.

The solvent was removed under reduced pressure and the crude product was purified by column chromatography on SiO₂ (Cyhex/EtOAc; 6:1). The desired product **ItaCORM 4b** was

obtained in form of a clear yellow oil in a yield of 69 mg (191 μ mol, 74%). The product crystallized upon storage.

M (C ₁₅ H ₁₄ FeO ₇)	362.12 g/mol. 0^{4}	
Yield	69 mg (191 μ mol, 74%)	Fe(CO)-
R _f	0.40 (SiO ₂ , Cyhex/EtOAc; 5:1).	13
¹ H NMR	(500 MHz, CDCl ₃): δ [ppm] = 6.34 (s, 1H, H-5a), 5.72 (d, J = H-5b), 5.43 (dd, J = 4.5, 1.2 Hz, 1H, H-8), 5.23 – 4.99 (m, 1H (s, 3H, H-6), 3.35 (d, J = 1.1 Hz, 2H, H-3), 3.11 (dddd, J = 6 1.5 Hz, 1H, H-10), 2.23 – 2.10 (m, 1H, H-12a), 1.97 – 1. H-11a, H-12b), 1.75 – 1.66 (m, 1H, H-11b).	1.1 Hz, 1H, , H-9), 3.69 .3, 3.8, 2.4, 81 (m, 2H,
¹³ C NMR	(125 MHz, CDCl ₃): δ [ppm] 211.2 (C13), 171.1 (C-4), 164.6 ((C-2), 129.2 (C-5), 103.8 (C-7), 80.8 (C-8), 80.5 (C-9), 60.5 ((C-1), 37.6 (C-3), 26.8 (C-12), 24.3 (C-11).	C-1), 133.8 C-10), 52.2
HR-MS (ESI)	calc.: [M+Na] ⁺ = 384.99812 amu found: 384.9980	3 amu.
FT-IR	(ATR): ṽ [cm ⁻¹] = 3007 (w), 2953 (w), 2919 (w), 2869 (w), 285 (s), 1957 (s), 1729 (s), 1641 (w), 1471 (w), 1456 (w), 1436 (m 1383 (w), 1339 (m), 1319 (m), 1261 (m), 1179 (m), 1134 (s) 1006 (m), 955 (m), 942 (m), 905 (m), 865 (m), 839 (w), 811 (m 740 (w), 637 (m), 611 (s), 560 (s), 540 (w), 517 (w).	8 (w), 2045), 1404 (w),), 1067 (w), n), 760 (w),

1.4 In situ quantification of CO-release

1.4.1 Headspace-GC-system

For the CO-release quantification a *Thermo Scientific* Trace 1300 headspace gas chromatograph equipped with a TriPlus RSH autosampler was used. The detector was a thermal conductivity detector (TCD). The system was equipped with a Shin carbon ST 10/120 1.0 mm x 2 m 1/16" OD silico column. For the programming of the system *Chromeleon*[®] 7 Data System Software was used.

1.4.2 Gas-chromatography conditions for GC-Headspace system

Helium was used as carrier gas with a flow of 15 mL/min. Injector temperature: 200 °C. Split flow 150 mL/min, split rate 10. Detector temperature: 200 °C.

Method description: 0 - 2.5 min at 35 °C, then heated to 70 °C with a 20 °C/min rate, kept 1 min at 70 °C and then cooled to 35 °C with a 20 °C/min rate and kept 1 min at 35 °C. Injection volume: 50 μ L

1.4.3 Calibration

Eight headspace vials (VWR, cat. No. 548-0090, vial headspace clear glass, 10 mL) were charged with DMSO (0.2 mL) and phosphate buffer solution (1.0 mL, pH = 7.4). The vials were sealed with gas-tight silicone/PTFE septa aluminium crimp caps (BGB Analytics, Cat. No. 20030500) and degassed with N₂.

A defined gas volume of the vial was substituted for CO (0.00 mL, 0.05 mL, 0.10 mL, 0.25 mL, 0.50 mL, 1.00 mL, 1.50 mL, 2.00 mL). The vials were then equilibrated at 37 °C for 10 min and the composition of the gas phase was subsequently determined by headspace GC analysis. The respective measurements were repeated three times and a calibration curve was then generated.

1.4.4 In situ quantification of the CO-release of ItaCORMs

The respective complex (36 μ mol) was dissolved in DMSO (0.2 mL) and phosphate buffer solution (1.0 mL, pH = 7.4). Pig liver esterase (PLE) (15 mg, 24 units/mg) was added and the mixture was stirred at 37 °C. The amount of CO released was determined *via* headspace GC analysis using the previously generated calibration curve. Control samples without addition of PLE were analyzed according to the same procedure.



Fig. 1: Enzyme-triggered CO-release of ItaCORM 1a with PLE (blue) and without PLE (red).



Fig. 2: Enzyme-triggered CO-release of ItaCORM 1b with PLE (blue) and without PLE (red).



Fig. 3: Enzyme-triggered CO-release of ItaCORM 2a with PLE (blue) and without PLE (red).



Fig. 4: Enzyme-triggered CO-release of ItaCORM 2b with PLE (blue) and without PLE (red).



Fig. 5: Enzyme-triggered CO-release of ItaCORM 3a with PLE (blue) and without PLE (red).



Fig. 6: Enzyme-triggered CO-release of ItaCORM 3b with PLE (blue) and without PLE (red).



Fig. 7: Enzyme-triggered CO-release of ItaCORM 4a with PLE (blue) and without PLE (red).



Fig. 8: Enzyme-triggered CO-release of ItaCORM 4b with PLE (blue) and without PLE (red).

1.5 NMR-Spectra

1.5.1 1 H (300 MHz, CDCI₃) and 13 C (75 MHz, CDCI₃) spectra of diethyl itaconate (DEI, 13)







1.5.3 1 H (500 MHz, CDCI₃) and 13 C (125 MHz, CDCI₃) spectra of ItaCORM 1a









1.5.7 ^{1}H (500 MHz, CDCl3) and ^{13}C (125 MHz, CDCl3) spectra of ItaCORM 3a



1.5.8 1 H (500 MHz, CDCI₃) and 13 C (125 MHz, CDCI₃) spectra of ItaCORM 3b



1.5.9 1 H (500 MHz, CDCI₃) and 13 C (125 MHz, CDCI₃) spectra of ItaCORM 4a



1.5.10 $\,^1\text{H}$ (500 MHz, CDCI₃) and ^{13}C (125 MHz, CDCI₃) spectra of ItaCORM 4b

170 160 150 140 130 120 110 f1 (ppm) 220 210

1.6 Crystal data and structure refinement

1.6.1 ItaCORM 3b

CCDC	<u>2077461</u>	
Identification code	bhd_kse9_nm (= ItaCORM 3	3b)
Empirical formula	C15 H14 Fe O7	
Moiety formula	C15 H14 Fe O7	
Formula weight	362.11	and the second s
Temperature	100(2) K	Y L X
Wavelength	1.54178 Å	
Crystal system	Monoclinic	•
Space group	P21	
Unit cell dimensions	a = 7.1067(3) Å	a= 90°.
	b = 12.2043(5) Å	b= 104.110(2)°.
	c = 9.3734(4) Å	g = 90°.
Volume	788.45(6) Å ³	
Z	2	
Density (calculated)	1.525 Mg/m ³	
Absorption coefficient	7.987 mm ⁻¹	
F(000)	372	
Crystal size	0.150 x 0.100 x 0.030 mm ³	
Theta range for data collection	4.865 to 71.892°.	
Index ranges	-8<=h<=8, -15<=k<=15, -11	<=l<=11
Reflections collected	14895	
Independent reflections	3057 [R(int) = 0.0603]	
Completeness to theta = 67.679°	99.9 %	
Absorption correction	Semi-empirical from equivale	ents
Max. and min. transmission	0.7535 and 0.4517	
Refinement method	Full-matrix least-squares on	F ²
Data / restraints / parameters	3057 / 1 / 210	
Goodness-of-fit on F ²	1.071	
Final R indices [I>2sigma(I)]	R1 = 0.0431, wR2 = 0.1008	
R indices (all data)	R1 = 0.0471, wR2 = 0.1039	
Absolute structure parameter	0.467(8)	
Extinction coefficient	n/a	
Largest diff. peak and hole	1.104 and -0.293 e.Å ⁻³	

1.6.2 ItaCORM 4b

CCDC	<u>2077462</u>		
Identification code	bhd_kse10n (= ItaCOR	RM 4 b)	
Empirical formula	C15 H14 Fe O7	5 8	
Moiety formula	C15 H14 Fe O7	► • • • •	P
Formula weight	362.11		0
Temperature	100(2) K		
Wavelength	1.54178 Å	C C C	
Crystal system	Orthorhombic	e	
Space group	Pbcn		
Unit cell dimensions	a = 11.3484(2) Å	a= 90°.	
	b = 7.47810(10) Å	b= 90°.	
	c = 36.7370(6) Å	g = 90°.	
Volume	3117.67(9) Å ³		
Z	8		
Density (calculated)	1.543 Mg/m ³		
Absorption coefficient	8.079 mm ⁻¹		
F(000)	1488		
Crystal size	0.150 x 0.150 x 0.030 ı	mm ³	
Theta range for data collection	4.580 to 72.285°.		
Index ranges	-13<=h<=10, -9<=k<=9), -45<=I<=45	
Reflections collected	33111		
Independent reflections	3074 [R(int) = 0.0511]		
Completeness to theta = 67.679°	99.9 %		
Absorption correction	Semi-empirical from equivalents		
Max. and min. transmission	0.7536 and 0.3992		
Refinement method	Full-matrix least-square	es on F ²	
Data / restraints / parameters	3074 / 0 / 209		
Goodness-of-fit on F ²	1.093		
Final R indices [I>2sigma(I)]	R1 = 0.0360, wR2 = 0.	0935	
R indices (all data)	R1 = 0.0381, wR2 = 0.	0945	
Extinction coefficient	n/a		
Largest diff. peak and hole	1.342 and -0.511 e.Å ⁻³		

2 Biology – Experimental Procedures

2.1 Animals

For the experiments performed, primary dendritic cells were isolated from C57BL/6 mice aged 8 weeks or older. The animals were bred and held in the facilities of the Eberhard Karls University Tübingen under specific pathogen free conditions. Mice were handled in accordance with the guidelines of the local authorities (Regierungspräsidium Tübingen, Germany).

2.2 Isolation of primary dendritic cells

The isolation of bone marrow derived dendritic cells (BMDCs) was performed according to a protocol of Madaan *et al.*.⁴ Initially, the bone marrow was isolated from femurs and tibias of C57BL/6 mice. After erythrocyte lysis, the cell suspension was plated with $2x10^6$ cells/ml on petri dishes (non-tissue culture grade). The culture medium consisted of DMEM supplemented with 10 % fetal calf serum, 1 % non-essential amino acids, 1 % sodium pyruvate, 1 % HEPES, 1 % antibiotics, 25 μ M ß-mercaptoethanol and 20 ng/ml recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). On day 3 and day 6 after plating of the cells, replenishment of culture medium was conducted by addition of fresh medium. Immature dendritic cells were harvested on day 7 by careful collection of non-adherent cells. Finally, immature BMDCs were plated for subsequent *in vitro* experiments with 1x10⁶ cells/ml.

2.3 Viability

BMDCs were treated with 1 µg/ml LPS for 24 h and increasing concentrations of **ItaCORM**s. Then, cell viability was determined using two different methods: (i) the Cell Proliferation Kit II (XTT) from Merck KGaA and (ii) the Pierce LDH Cytotoxicity Assay Kit from Thermo Fisher Scientific. Analyses were performed as described in the manufacturer's protocols.

2.4 Western blot

For the analyses of the HO-1 and STAT1 signaling pathways, BMDCs were stimulated with 1 μ g/ml LPS and **ItaCORM**s or their corresponding reference substances for 2 h. Subsequently, Western blotting was performed as previously described in detail.⁵ In the present study, α -tubulin (1:5000; Novus Biologicals) was applied as loading control.

2.5 Analyses of cytokines

For the analyses of inflammatory cytokine levels, BMDCs were treated with 1 µg/ml LPS and **ItaCORM**s or their respective reference substances. After 24 h of stimulation, the cell culture supernatant was collected. Measurements of IL-12p70 and IL-23 concentrations were performed using the commercially available kits DuoSet ELISA Mouse IL-12p70, DuoSet ELISA Mouse IL-23 in combination with the DuoSet Ancillary Reagent Kit 2 from R&D Systems. The whole procedure was performed as described in the manufacturer's protocol.

3 Biology - Results



3.1 Determination of cell viability

Figure 9: Analysis of cell viability after ItaCORM treatment. BMDCs were treated with PBS, 1 µg/ml LPS and the indicated concentrations of **ItaCORM**s for 24 h. Cell viability was then measured using XTT (A) and LDH (B) assay. Shown is the percentage of viable cells (A) or cytotoxicity (B) in relation to the PBS-treated control. Values are means ± SEM (n=3).

3.2 ELISA





BMDCs were stimulated with 1 μ g/ml LPS and co-incubated with PBS, 15 μ M **ItaCORM**s or the respective reference substances. After 24 h incubation, the cell culture supernatant was harvested and analyzed for IL-23 (**A**) and IL-12p70 (**B**) concentrations. Values are means ± SEM; **, p ≤ 0.01; *****, p ≤ 0.0001 (ANOVA with Tukey post-hoc test).

4 References

- 1. A. F. Burchat, J. M. Chong and N. Nielson, *Organomet. Chem.*, 1997, **542**, 281-283.
- 2. P. Ferraboschi, S. Casati, P. Grisenti and E. Santaniello, *Tetrahedron*, 1994, **50**, 3251-3258.
- 3. K. Achiwa, P. A. Chaloner and D. Parker, *Organomet. Chem.*, 1981, **218**, 249-260.
- 4. A. Madaan, R. Verma, A. T. Singh, S. K. Jain and M. Jaggi, *J. Biol. Methods*, 2014, **1**, e1.
- B. Bauer, A.-L. Göderz, H. Braumüller, J. M. Neudörfl, M. Röcken, T. Wieder and H.-G. Schmalz, *Chem. Med. Chem.*, 2017, **12**, 1927-1930.